Published in Retina

Utilizing the Latest Equipment to Improve Vitrectomy Outcomes

This is editorially independent content supported by advertising from Bausch + Lomb
4 min read

Join Drs. Singh, Garg, and Kuriyan to review the Bi-Blade+ dual-port vitrectomy cutter and the Adaptive Fluidics advanced update for the Stellaris Elite system.

Since Robert Machemer developed the first vitreous cutter in the early 1970s, instrumentation has moved from 20-gauge systems, the historical standard, to 25-gauge systems introduced in 2002 and, more recently, 27-gauge systems.
Smaller incisions brought improvements in wound construction, operating time, post-operative inflammation, and complication rates. Development has since shifted toward cut rate and fluidics, because higher cut rates fragment vitreous into smaller pieces and reduce traction on the adjacent retina.1

“I migrated to 25, but … as you go up even to 27, you see the efficiency changes with the single port cutters that are available.”

In this episode of Evidence Based Retina, three retina surgeons discuss how recent advances in vitrectomy cutters and fluidics have changed intra-operative pressure control, cutting efficiency, and gauge selection.
Rishi P. Singh, MD, FASRS, hosts the discussion with Ajay Kuriyan, MD, of Mid Atlantic Retina and the Wills Eye Hospital Retina Service, and Sunir Garg, MD, FACS, director of the Retina Service at Mid Atlantic Retina/Wills Eye Hospital.

Bi-Blade+ fast facts

  • In April 2026, the FDA granted 510(k) clearance to the Bi-Blade+ dual-port vitrectomy cutter and the Adaptive Fluidics advanced update for the Stellaris Elite system. The cutter is indicated for anterior vitrectomy during anterior segment surgery and for vitreoretinal conditions requiring posterior or combined vitrectomy.2
  • Bi-Blade+ reaches 25,000 cuts per minute (cpm) with a dual-port design that doubles the cut rate of single-port cutters while maintaining a 100% duty cycle. It is available in 23-, 25-, and 27-gauge sizes.3,4
  • Compared with the original Bi-Blade, Bi-Blade+ demonstrated a 67% increase in cutter speed, 25% greater average vitreous flow, and 62% less vibration at maximum cut speed in ex vivo and in vitro testing.2,4
  • Iatrogenic retinal breaks remain a meaningful risk during induced posterior vitreous detachment (PVD). A 2026 retrospective study of 185 eyes undergoing 25- or 27-gauge macular surgery reported breaks in 15.1%, with 69% located inferiorly.5
  • Independent clinical data on dual-blade cutters remain limited. A randomized controlled trial compared a 25-gauge 20,000-cpm dual-blade cutter with a 10,000-cpm single-blade cutter:6
    • Overall core vitrectomy time did not differ significantly (269 vs. 289 seconds; P = 0.347).
    • The dual-blade cutter was significantly faster in epiretinal membrane eyes (241 vs. 291 seconds; P = 0.03).
    • No intra-operative iatrogenic breaks occurred in either arm.

How Bi-Blade+ and Adaptive Fluidics stabilize IOP

Intraocular pressure (IOP) is the problem that most often changes early management after vitrectomy. In a Wills Eye cohort of 418 vitrectomies for rhegmatogenous or tractional retinal detachment, every management change at post-operative day one was made to treat elevated IOP.7 Silicone oil tamponade showed a trend toward higher day-one IOP that did not reach statistical significance (relative risk 3.23; P = 0.06).7
When a trainee aspirates balanced salt solution rather than vitreous, fluid leaves the eye faster than many systems replace it, and the eye softens until the console compensates. Dr. Singh, who operates on an older non-Bausch platform, raises his baseline infusion pressure to offset that lag.
Adaptive Fluidics instead adjusts infusion automatically in response to the surgeon’s real-time vacuum commands.2 Dr. Kuriyan, a Stellaris Elite user, sets IOP at 25mmHg for most cases and lower in diabetic eyes at risk of ischemia.

“With the more recent advancements, we’ve been able to compensate for that with Adaptive Fluidics and be able to maintain the pressure in the eye a lot better than in previous iterations of the machine.”

Clinical data on IOP stability during surgery

Paired with Adaptive Fluidics, Bi-Blade+ produced a 62% reduction in average infusion pressure compared with surgery without Adaptive Fluidics. Chamber IOP also stayed closer to the physiologic range of 10 to 20mmHg, even at high vacuum levels.2,8 The continuous aspiration of a 100% duty cycle contributes to that stability.2 With the original Bi-Blade, Adaptive Fluidics cut the drop in operating IOP in half.3
Port design also determines how much suction a surgeon can generate when elevating a firmly adherent hyaloid. Dr. Garg uses the cutter for PVD induction. He also throttles the foot pedal to turn it into a single-action scissor for segmenting and delaminating diabetic membranes.

“I can generate a lot of suction very rapidly, and that helps me be able to peel a [hyaloid] even in cases where it’s really firmly adherent.”

The Bi-Blade+ performance figures come from bench testing and conference abstracts, not from peer-reviewed clinical outcome studies.2,4,8 Whether they translate into fewer iatrogenic breaks or better visual outcomes has not yet been established.

In closing

Current vitrectomy platforms gain efficiency mainly through cut rate, duty cycle, and automated infusion control rather than through smaller incisions. For surgeons evaluating new equipment, the strongest current argument for Bi-Blade+ with Adaptive Fluidics is more stable IOP at high vacuum, and clinical outcome data are the next evidence to watch for.

This article was written by Mariel Mohns, MS, based on the conversation between Drs. Singh, Garg, and Kuriyan.

  1. Chow SC, Lo JMY, Quddus M, et al. Performance, safety and efficiency comparison between a 25G 20,000 and a 10,000 cuts per minute vitrectomy: a prospective randomized control study. Int J Retina Vitreous. 2025;11(1):45. doi:10.1186/s40942-024-00613-w
  2. Bausch + Lomb. Bausch + Lomb receives FDA 510(k) clearance for Bi-Blade+ dual-port vitrectomy cutter and Adaptive Fluidics advanced update. Business Wire. April 8, 2026. Accessed October 15, 2026. https://businesswire.com/news/home/20260408564994/en/.
  3. Tewari A, Houston SK, Chang E. The new retina OR: the latest vitrectomy tools. Retina Today. January/February 2026. Accessed October 15, 2026. https://retinatoday.com/articles/2026-jan-feb/the-new-retina-or-the-latest-vitrectomy-tools
  4. Bausch + Lomb. Bi-Blade+. Bausch Surgical. Accessed October 15, 2026. https://www.bauschsurgical.com/retina/bi-blade-plus/
  5. Paris JE, Macri CZ, Agrawal S, Lake S, Chan WO. Risk factors for iatrogenic retinal breaks during induction of posterior vitreous detachment in macula surgery. Int Ophthalmol. 2026 Jul 12;46(1):287. doi: 10.1007/s10792-026-04162-z. PMID: 42437431; PMCID: PMC13357438.
  6. Chow SC, Lo JMY, Quddus M, et al. Performance, safety and efficiency comparison between a 25G 20,000 and a 10,000 cuts per minute vitrectomy: a prospective randomized control study. Int J Retina Vitreous. 2025;11(1):45. doi:10.1186/s40942-024-00613-w
  7. Patel D, Borkar DS, Madhava M, et al. Incidence of management changes at the postoperative day one visit after pars plana vitrectomy for retinal detachment. Am J Ophthalmol. 2021;222:271-276. doi:10.1016/j.ajo.2020.09.034
Rishi P. Singh, MD, FASRS
About Rishi P. Singh, MD, FASRS

Rishi P. Singh, MD, FASRS, is the Chair of the Department of Ophthalmology at Mass General Brigham, overseeing ophthalmology across Massachusetts Eye and Ear, Massachusetts General Hospital, Brigham and Women’s Hospital, and affiliated sites. He is also a Professor of Ophthalmology at Harvard Medical School.

Previously, Dr. Singh served as Vice President and Chief Medical Officer at Cleveland Clinic Martin Health in Stuart, Florida, and as a staff surgeon at the Cleveland Clinic, where he was also Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio. He received both his undergraduate degree in medical science and his medical degree from Boston University, completing his internship at Tufts University. Dr. Singh went on to complete his ophthalmology residency at the Massachusetts Eye and Ear Infirmary/Harvard Medical School and a medical and surgical vitreoretinal fellowship at the Cole Eye Institute at the Cleveland Clinic.

Dr. Singh specializes in the management of complex retinal diseases, including diabetic retinopathy, retinal vein occlusions, retinal detachment, and age-related macular degeneration. He has authored over 300 peer-reviewed publications, books, and book chapters and serves as Principal Investigator for numerous national and international clinical trials aimed at improving outcomes for patients with retinal diseases.

He is the founder and past president of the Retina World Congress, chairs some of the largest continuing medical education meetings in retina, and serves on editorial boards and review panels for major ophthalmology journals. His leadership has extended into digital innovation, having helped lead enterprise-wide implementation of clinical technologies including Epic modules, digital informed consent, and patient-facing kiosks.

Dr. Singh has received multiple accolades for his contributions to ophthalmic research and innovation, including the Alpha Omega Alpha Research Award, the American Society of Retina Specialists Young Investigator Award, and the J. Donald Gass Beacon of Sight Award. He also leads The Center for Ophthalmic Bioinformatics, a research initiative focused on leveraging big data and artificial intelligence to advance understanding and treatment of retinal disease.

Rishi P. Singh, MD, FASRS
Sunir J. Garg, MD, FACS, FASRS
About Sunir J. Garg, MD, FACS, FASRS

Sunir J. Garg, MD, FACS, FASRS is a Professor of Ophthalmology on the Retina Service at Wills Eye Hospital and Thomas Jefferson University, and a partner at Mid Atlantic Retina. He also serves as Co-Director of the Retina Research Unit at Wills Eye Hospital and is the principal investigator for numerous national and international clinical trials.

Dr. Garg earned his Bachelor of Science with Honors and Doctor of Medicine degrees from the University of Michigan, where he completed his ophthalmology residency and was appointed Chief Resident. He completed his fellowship training in vitreoretinal surgery at Wills Eye Hospital.

A nationally and internationally recognized leader in retina care and research, Dr. Garg has authored more than 600 peer-reviewed publications and book chapters and edited or co-edited four major textbooks. He is the former Editor-in-Chief of Retina Times and currently serves as Ophthalmology Editor for the Merck Manual and Editor-in-Chief of the American Academy of Ophthalmology ONE Network. He serves on the editorial boards of the American Journal of Ophthalmology and the Canadian Journal of Ophthalmology and is Managing Editor of Ophthalmic Research. He also serves on the American Diabetes Association Standards of Care Committee.

Dr. Garg is a past president of the Greater Philadelphia Ophthalmology Society and former Chair of the Wills Eye Annual Conference. He is a clinical spokesperson for the American Academy of Ophthalmology, serves on its Ethics Committee, and is Chair of the Academy’s Annual Meeting Retina Committee. His honors include two Secretariat Awards from the American Academy of Ophthalmology, the Senior Honor Award from the American Society of Retina Specialists, and the inaugural Women in Retina Champion Award.

He is a member of the Retina Society, Macula Society, American Academy of Ophthalmology, American Uveitis Society, and the American Society of Retina Specialists, and serves on the boards of the American Society of Retina Specialists and the Macula Society.

Clinically, Dr. Garg specializes in the treatment of diabetic retinopathy, age-related macular degeneration, complex retinal detachments, retinal vascular diseases, inherited retinal degenerations, macular holes and puckers, and ocular inflammatory conditions.

Dr. Garg is frequently featured in national media, including The Wall Street Journal, USA Today, The Philadelphia Inquirer, and Real Simple, as well as The Atlantic, Popular Science, Women’s Health, and Billboard. He has also appeared on Medscape/WebMD, NPR’s The Pulse, Fox 29 Philadelphia, CBC, Today, and Good Morning America.

Sunir J. Garg, MD, FACS, FASRS
Ajay E. Kuriyan, MD
About Ajay E. Kuriyan, MD

Dr. Ajay E. Kuriyan is a vitreoretinal specialist. He graduated with Honors in dual majors of Biology and Health and Society from University of Rochester, and received his Doctor of Medicine degree, with academic distinction and honors in research, from University of Rochester as well. He then completed an internship at the Mount Sinai Medical Center, and completed his ophthalmology residency at Bascom Palmer Eye Institute, where he was selected as Chief Resident. Dr. Kuriyan also completed his retina fellowship at Bascom Palmer Eye Institute.

During his training he was the recipient of numerous prestigious awards including the induction into Alpha Omega Alpha and the Gold Humanism Society, Heed Fellowship, Evangelos S. Gragoudas Award, and the Lee Family Community Service Award.

Dr. Kuriyan is board certified in ophthalmology. He is an active member of the Retina Service at Wills Eye Hospital and is an Associate Professor of Ophthalmology at Sidney Kimmel Medical College of Thomas Jefferson University. He is an innovative surgeon; he performed the first Argus implant surgery in NY state and reported the first case of pre-retinal amniotic membrane for refractory macular holes.

He is a member of the American Academy of Ophthalmology, American Society of Retina Specialists, Macula Society, Retina Society, and the Association for Research in Vision and Ophthalmology. He serves on several committees for these societies. He has received numerous recognitions for his expertise, including the ASRS’ Presidential Award, Senior Honor Award, and Honor Award, AAO’s Secretariat Award and Achievement Award, Real World Ophthalmology Remarkable Research Award, Ophthalmology Management Top 40 under 40, and Castle Connolly and Philadelphia Magazine Top Doctor recognitions.

Dr. Kuriyan has authored and edited over 250 scientific publications, abstracts, editorials, and textbook chapters on vitreoretinal diseases. He has been an invited speaker to present scientific papers and abstracts at national and international ophthalmic meetings and invited as a visiting professor at several academic programs. He is actively involved as a clinical investigator in several collaborative trials and studies on various conditions including age-related macular degeneration, diabetic retinopathy, refractory macular holes, retinal detachment repair, and novel retinal surgical techniques.

Dr. Kuriyan conducts translational research that focuses on proliferative vitreoretinopathy, a scar forming process that is the most common cause of recurrent scarring after retinal detachments. His research includes establishing a novel model for studying proliferative vitreoretinopathy and better understanding the mechanisms of proliferative vitreoretinopathy to identity new treatments for the disease process.

He has also worked on collaborations to better assess the impact of therapeutics on retinal vascular diseases using novel imaging techniques and machine learning. He has been awarded multiple research grants for his research including funding from the Macula Society, the Retina Society, the Alcon Research Institute, and the NEI.

Dr. Kuriyan was raised in Queens, NY and has now set roots in the Philadelphia area with his wife, and two children. He values providing outstanding, compassionate care to patients while having the opportunity to conduct ground-breaking clinical and translational research studies and being actively involved in the education of the high caliber trainees at Wills Eye Hospital.

Ajay E. Kuriyan, MD
💙 Evidence Based Retina
Astellas
Regeneron
Bausch + Lomb Bi-Blade
EyePoint, Inc.
Apellis Pharmaceuticals
Norlase